Quidel (QDEL) Osake Kurssi

Quidel Corp is primarily active in the healthcare industry, specifically specializing in diagnostic testing solutions. As a prominent player in the medical diagnostics market, Quidel Corp offers a wide range of diagnostic tests and systems for various applications. These include tests for influenza, respiratory syncytial virus, strep throat, and more. With a strong focus on rapid and accurate diagnostic solutions, Quidel Corp continues to contribute to the advancement of healthcare through its innovative products and services.

The main competitors of Quidel Corp in the market include Beckman Coulter Inc., Abbott Laboratories, and Bio-Rad Laboratories Inc. These companies operate in the same industry as Quidel Corp and provide similar products and services. Beckman Coulter Inc. is known for its wide range of diagnostic systems, while Abbott Laboratories is a global healthcare company offering various medical devices. Bio-Rad Laboratories Inc. specializes in life science research and clinical diagnostics. Despite competition, Quidel Corp has carved a niche for itself with its innovative diagnostic solutions and remains a strong player in the market.

Quidel Corp is a leading healthcare diagnostic company founded in 1979. Headquartered in San Diego, California, Quidel Corp specializes in developing, manufacturing, and marketing rapid medical diagnostic solutions. With a focus on infectious diseases, women's health, and gastrointestinal diseases, Quidel Corp has played a crucial role in improving patient outcomes worldwide. Over the years, the company has gained recognition for its innovative products, such as rapid immunoassays and histofluorescence systems. Quidel Corp's commitment to advancing healthcare has made it a trusted name in the industry, and its dedication to cutting-edge research and development continues to drive its success.

Quidel Corp, a leading molecular diagnostic company, has achieved several significant milestones. One noteworthy achievement is the development and FDA approval of their Sofia® Influenza A+B Assay, which enables rapid and accurate diagnosis of influenza infections. Additionally, Quidel launched a revolutionary molecular diagnostic platform called Solana®, capable of detecting and identifying a range of infectious diseases. Furthermore, the company received Emergency Use Authorization from the FDA for their Highly Accurate, Scalable, and Rapid (HASR) Antigen Test for COVID-19, aiding in the global battle against the pandemic. Quidel Corp continues to demonstrate its commitment to innovation, improving healthcare outcomes with its cutting-edge diagnostic solutions.

Quidel Corp is primarily present in the United States, with headquarters in San Diego, California. The company operates globally and has a strong presence in various countries and regions. Quidel Corp has established significant market penetration in Canada, Europe, Latin America, the Asia-Pacific region, and the Middle East. Their commitment to expanding healthcare solutions and diagnostic products spans across multiple continents, aiming to improve healthcare outcomes worldwide. With a focus on innovation and a growing global footprint, Quidel Corp continues to make its mark in the medical diagnostics industry across diverse geographic locations.

Quidel Corp represents values of innovation, collaboration, and excellence. With a strong corporate philosophy centered around improving healthcare outcomes, Quidel Corp is committed to delivering accurate diagnostic solutions for various diseases. By continuously investing in research and development, the company aims to develop cutting-edge technologies to address critical medical needs. Quidel Corp's focus on quality and precision enables healthcare professionals to make informed decisions, ultimately benefiting patients worldwide. Through strategic partnerships and a customer-centric approach, Quidel Corp remains dedicated to advancing the field of diagnostic testing and ensuring the highest standards of patient care.

Analyytikot asettavat tällä hetkellä Quidel-osakkeelle keskimääräisen tavoitehinnan 12,25 USD (mediaani: 12,25 USD), mikä merkitsee −0,5 % viimeisimpään hintaan verrattuna. Konsensus perustuu 8 analyytikkoarvioon.

Quidel Analyytikkojen kursstavoitteet 2026

8 analyytikkoa arvioi tällä hetkellä Quidel-osaketta: 1 suosittaa ostoa, 3 pitoa ja 4 myyntiä. Vuodelle 2026 analyytikot odottavat Quidel-yhtiöltä 2,54 Mrd. USD liikevaihtoa ja 0,77 USD osakekohtaista tulosta.

Quidel Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Quidel-osake noteerataan hintaan 10,98 EUR (12,31 USD).

Quidel-osake (QDEL) on listattuna 1 pörssissä, muun muassa: NASDAQ (QDEL).

The Quidel Corporation is a leading company in the development and production of diagnostic rapid tests for various areas such as infectious diseases, cardiovascular diseases, and women's health. The company is headquartered in San Diego, California and operates production facilities in the USA and Europe. Quidel has specialized in a wide range of products and applications in the field of rapid diagnostics in recent years. The main product categories are: influenza tests, tests for infectious diseases such as COVID-19, gastrointestinal tests, tests for women's health, and tests for monitoring cardiovascular diseases. Quidel's influenza tests provide a fast and accurate means of detecting acute respiratory infections. These tests are especially important for rapidly identifying cases of flu in hospitals and in the public. The company also develops tests that can test for multiple types of influenza viruses. Tests for infectious diseases are an important category for Quidel. The company offers a variety of tests for COVID-19 and has achieved great success in this area. The products for COVID-19 include both molecular and antigen-based tests. The molecular test system can quickly and reliably detect an infection with the virus. The antigen test allows medical personnel to quickly perform a screening within 15 minutes. Quidel responded quickly to the pandemic and has increased its production capacity. Tests for gastrointestinal diseases are also important for the company. The portfolio includes tests for Helicobacter pylori infections, Clostridium difficile, and rotavirus. These tests are crucial for the rapid and accurate diagnosis of gastrointestinal diseases and can be used by a variety of medical professionals. Tests for women's health is a growing market for the company. It is known that many women are diagnosed with ovarian tumors and gynecological cancers. Quidel has developed a wide range of tests for women's health that enable the rapid diagnosis of tumors and infections. The company has also introduced a new product line for monitoring heart diseases. These tests measure various markers in the blood to determine if a person has an increased risk of cardiovascular diseases. These tests are useful for medical professionals to quickly identify at-risk patients. Quidel sells its products directly to medical professionals as well as through wholesalers. The company has strong relationships with its distribution partners and is committed to increasing its product presence in retail. Ongoing product updates and developments are an important part of the business strategy to serve the market. Conclusion: Quidel Corporation is a leading provider of diagnostic rapid tests for various industries. The company has a wide range of products and is committed to increasing its presence in various markets. With strong relationships with distribution partners and advanced product differentiation, Quidel is well positioned to continue achieving growth.

odotettu liikevaihto Quidel on 2,54 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Quidel on 52,49 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Quidel:n hinta-voitto-suhde (P/E) on tällä hetkellä 15,90. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Quidel-osakkeen arvostusta.

Quidel:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,33. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Quidel-osakkeen arvostuskennuslukuna.

Quidel:n Eulpool-laatuscore on 2/10.

Quidel:n ISIN on US74838J1016. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Quidel:n WKN on 867261. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Quidel:n ticker on QDEL. Tämä pörssinoteeraus käytetään Quidel-osakkeiden kauppaan pörssissä.